Carb-X

Live Webinar: GARDP/REVIVE – Clinical development of antimicrobials – Phase 1 development challenges
2020-06-30 11:00 - 12:30 (America/New_York) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speaker: Markus Zeitlinger, Head of Department of Clinical Pharmacology, Medical University of Vienna (Austria)
Moderator: Markus Heep
The presentation will be followed by a Q&A session.
Register now for this live webinar including interactive Q&A session on 30 June, 17:00-18:30 CEST. Find your time zone here.

Live Webinar: GARDP/REVIVE – The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study
2020-07-09 03:00 - 04:30 (America/New_York) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speakers:

Anand Anandkumar, Co-founder and CEO Bugworks Research Inc (India)
Kamini Walia, Program Officer, ICMR-AMR Initiative (India)

Moderator: François Franceschi, GARDP
In this webinar, Anand Anandkumar and Kamini Walia will discuss:

Why is India one of the hotbeds of the AMR problem? Latest statistics of growing drug resistance etc.
Initiatives of the Indian Government to curb the AMR problem
Antimicrobial R&D landscape in India – a vibrant ecosystem supporting innovation in AMR diagnosis, prevention and therapeutics
Fledgling antimicrobial clinical trial networks – could trials out of India play a significant role in gaining global regulatory approvals?
Changing regulatory environment to enable accelerated approvals for antimicrobial products

The presentation will be followed by a Q&A session.
Register now for this live webinar including interactive Q&A session on 5 May 2020, 9:00-10:30 am CEST (find your time zone here).

Longitude Prize Sprint Workshop 1 - Navigating MedTech Regulation Pathways in Developed and Emerging Markets
2020-08-07 10:00 - 15:00 (America/New_York) | Webinar
In July 2020, the Longitude Prize is launching the Longitude Prize Sprint Programme. The Sprint programme is free and will consist of a mix of Sprint Workshops and Sprint 1:1 Expert Support and is perfect for people and teams working in the field of AMR diagnostic test development. The Longitude Prize will be running three Sprint Workshop webinars from July to November 2020. The Sprint Workshops (virtual webinars) are open to all Longitude Prize Competitors, along with diagnostic test developers who are looking for technical advice and support for regulatory pathways, finance and investment, and manufacture and distribution strategies.

Longitude Prize Sprint Workshop 1 – Navigating MedTech Regulation Pathways in Developed and Emerging Markets

Medtech product development and commercialisation for devices and diagnostics is a complex process and has a long gestation period. There are many uncertainties that Medtech product development has to navigate especially during technology development and validation stages of product development as well as being able to meet regulatory standards. Successful navigation of the regulatory maze is important in product development roadmap.
There are subtle and distinct variations in regulatory standards for Medtech products across different geographies especially between developed and developing countries. Another layer of complexity is the continuous change in regulatory landscapes both in mature and evolving markets across the world.
The workshop (virtual webinar), as part of the Longitude Prize Sprint programme, will draw upon insights from experts in Medtech regulation and address the nuances of regulation in different geographies which will guide Medtech companies in their product development strategies.

To learn more, click here.

BIOCOM 4th AMR Conference: Novel Antimicrobials and AMR Diagnostics
2020-08-24 - 2020-08-28 | Webinar
This year’s digital AMR Conference will be an international forum to discuss AMR in the context of COVID-19 and beyond.
CARB-X speakers include Kevin Outterson, Executive Director, Erin Duffy, Chief of Research and Development, and Betsy Wonderly Trainor, Alliance Director.
The current global health crisis caused by COVID-19 shows more than ever the importance of infectious diseases expertise and the high need for further fighting against antimicrobial resistance (AMR). A cross-sectoral international dialogue with all stakeholders involved will be crucial to help implement innovative therapies and diagnostics in the clinical practice globally.
Together with our supporters – among others our major partner, the BEAM Alliance – the AMR Conference will continue to provide a (virtual) platform for those debates bringing together stakeholders from industry, SMEs, start-ups, academia, clinics, investors, public institutions and policy. Within our digital AMR Conference Week in August, we want to catch up discussing the challenges of bringing new antimicrobial treatments and diagnostics into the market and as a result, help to establish a post-COVID policy roadmap on AMR.
Five days of insights and networking for the global AMR community: Each conference day will cover a focus topic with selected LIVE sessions and high-level panels. Additionally, you will be able to explore scientific poster presentations and participate in virtual 1:1 meetings throughout the whole week and to engage within our new digital AMR stakeholder platform which is currently being set up.

Click here to view the programme.
Click here to learn more.
Click here to register.

BIOCOM 4th AMR Conference: Business models | The AMR company of the future – Which route to success
2020-08-25 07:30 - 09:00 (America/New_York)
Moderator:

Erin Duffy – Chief of Research & Development, CARB-X

Speakers:

Jonathan Butcher – Head of Business Development, BioVersys AG
Cherif Bousselham – Senior Vice President, Head of Sales, EMEA, Accelerate Diagnostics Inc.
Jean-Pierre Paccaud – Director of Business Development and Corporate Strategy, GARDP
Kenneth Bradley – Global Head, Infectious Disease Discovery, Roche

BIOCOM 4th AMR Conference: Business models in AMR | How to develop strategic decisions in a challenging and global AMR market
2020-08-25 09:15 - 10:15 (America/New_York) | Webinar
Moderator:

Gökhan Batur – CEO, Polyphor Ltd

Speakers:

Peter Beyer – Senior Advisor Department of Essential Medicines & Health Products, WHO
Erin Duffy – Chief of Research & Development, CARB-X
Holger Zimmermann – CEO, AiCuris

BIOCOM 4th AMR Conference: AMR pull incentives | Will COVID-19 speed up or slow down implementation?
2020-08-25 10:30 - 11:45 (America/New_York) | Webinar
Moderator:

Kathy Talkington, Director Health Programs, Pew Charitable Trust

Speakers:

Colm Leonard – Clinical Advisor/Consultant, NICE
Kevin Outterson – Professor of Law & Executive Director, CARB-X
Elmar Nimmesgern – Secretariat Lead, Global AMR R&D Hub
Daniel Berman – Lead of the Global Health Team, Longitude Prize / Nesta

Bacteriophage Therapy Summit
2020-08-27 - 2020-08-28 | Webinar
As the scientific community search for alternatives to broad spectrum antibiotics, phage therapy has re-emerged as a viable solution to tackle the global health challenge of anti-microbial resistance.
As such, the 2nd Bacteriophage Therapy Summit returns digitally as a dedicated platform for leaders in industry and academia to accelerate the discovery and translation of bacteriophage research into targeted therapeutics that demonstrate clinically significant results.
With a heavy translationally focused agenda including how to overcome bacterial resistance scaling-up manufacturing and showing clinical efficacy this is your opportunity to join your peers to strengthen your product development pipelines and forge collaborations to unlock the full potential of bacteriophage therapeutics.
View the full event guide for further details on speakers, content and how to join those who paving the way for bacteriophage-based therapeutics!

BIOCOM 4th AMR Conference: SME campus (Part II) | Focus on diagnostics
2020-08-27 06:00 - 07:00 (America/New_York) | Webinar
Moderator:

Betsy Wonderly Trainor, Alliance Director, CARB-X

Speakers:

Peter Haug – CFO & Co-Founder, Head of Business Development & Licensing, Noscendo GmbH
Piotr Gastrecki – CTO, ScopeFluidics
Rosemarie Preyer – GenID GmbH

PACCARB: Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria
2020-09-09 - 2020-09-10 | Webinar
The September PACCARB meeting, held virtually, will focus on welcoming eight new liaison members and on the impact of COVID-19 and its affect on antimicrobial resistance (AMR). Topics will include presentations on the COVID-19 mortality rate due to secondary acquired infections, antibiotic stewardship practices during a pandemic, disruptions in the agricultural industry due to COVID-19 and the intersection of AMR and emergency preparedness.
This virtual public meeting is hosted by HHS and is open to the public. It will be held via webcast.The meeting can be accessed through a live webcast on the day of the meeting.
Live Webcast: www.hhs.gov/live
Click here to learn more.

Building, Funding, and Growing Successful Biotech Startups
2020-09-17 14:00 - 15:30 (America/New_York) | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speakers include Cameron Bess, Project Officer, Antibacterials Branch, Division of CBRN Medical Countermeasures, BARDA.
Turning a good scientific idea into a successful biotech startup is a challenging journey.This panel will highlight several successful paths that scientists can take toward creating a successful biotech company. Learn what New York-area resources are available to turn your idea into a business and help you develop entrepreneurial skills.
The event will introduce funding and strategic programs available from IndieBio, the Center for Biotechnology, the National Institutes of Health (NIH), and the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
Speakers include:

Anton Xavier, Assistant Director of Technology and Business Development at the Center for Biotechnology.
Phuong Nguyen, Commercialization Fellow at the Center for Biotechnology.
Stephen Chambers, Managing Director of IndieBio in New York.
Matthew McMahon, Director of NIH’s Small Business Education and Entrepreneurial Development (SEED) Program.
Cameron Bess, Project Officer, Antibacterials Branch, Division of CBRN Medical Countermeasures, BARDA.

To learn more and register, click here.

Antimicrobial Resistance Fighter Coalition Webinar: Responding to difficult-to-treat infections: Role and responsibilities of governments, researchers, clinicians, industry and patients
2020-09-19 09:00 - 10:00 (America/New_York) | Webinar
AMR in the Light of COVID-19 – A Webinar Series
Each of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world.
About this Webinar:
Governments, researchers, and industry partners around the world have mobilized to develop diagnostics, therapeutics, and vaccines for COVID-19. The development of new recommendations and practices continue to be deployed to slow the spread of COVID-19. The burden of drug-resistant infections could surpass COVID-19. Drugs like antibiotics are a vital tool for modern medicine, used to prevent and treat infections. As drug-resistant infections are becoming more common, modern medicine as we know it is at risk and much like COVID-19, it has the potential to overwhelm our healthcare structure. What changes are needed to reshape strategies for combatting antimicrobial resistance globally?
To learn more about the Antimicrobial Resistance Fighter Coalition, click here.
To learn more about this webinar series, click here.
To register for this webinar, click here.

Chatham House Webinar: Creating a New Generation of Antibiotics
2020-09-22 07:00 - 08:00 (America/New_York) | Webinar
Participants include Kevin Outterson, Executive Director of CARB-X.
The world needs a new generation of antibiotics to address the rapid growth in antibiotic-resistant bacteria. The UK government’s 2014 Review on Antimicrobial Resistance estimated that such bacteria could result in the deaths of 10 million people a year by 2050 and an accumulated cost of up to $100 trillion to the global economy. Despite this urgent need, there remain few new antibiotics in development due to a lack of commercial viability for pharmaceutical companies with a 2019 Chatham House report highlighting the lack of progress being made on critical recommendations to tackle antimicrobial resistance.
This event will discuss the urgency of the development of new antibiotics and recent efforts to address the funding gap. What is the significance of the rise of antibiotic-resistant bacteria? What are the challenges at the intersection of increasing demand for new antibiotics and their commercial viability? Does the recent announcement of a new fund from the pharmaceutical industry represent a major shift, or just the beginning, of what is needed?
Participants:

Thomas Cueni, Director General, IFPMA
Jim O’Neill, Chair, Chatham House
Kevin Outterson, Associate Fellow, Global Health Programme, Chatham House
Laura Piddock, Professor of Microbiology; Deputy Director of the
Institute of Microbiology and Infection, University of Birmingham
Chair: Emma Ross, Senior Research Fellow, Global Health Programme, Chatham House

To learn more, click here.

ESCMID Conference on Coronavirus Disease (ECCVID)
2020-09-23 - 2020-09-25 | Webinar
Speakers include Kevin Outterson, Executive Director of CARB-X.
The ESCMID Conference on Coronavirus Disease (ECCVID) will take place online from Wednesday 23rd to Friday 25th September 2020 and will cover all aspects of COVID-19. ECCVID will feature a comprehensive scientific programme that will span a wide range of topics surrounding this emerging threat.
COVID-19 is a major public health incident which has brought about significant challenges and uncertainties with respect to diagnostics, therapeutics and infection prevention and control. We are learning continually about the new SARS-CoV-2 virus and an international scientific event that brings together the latest research and scientific evidence is very timely. ECCVID will offer excellent opportunities to showcase the latest findings, share experiences and knowledge and demonstrate practical techniques and guidance.
Internationally renowned clinical microbiologists, infectious diseases specialists and experts from related disciplines will present their work and latest findings on COVID-19, during the event.
Click here to learn more.
Click here to view the programme.
Click here to register.

Antimicrobial Resistance Fighter Coalition Webinar: The global movement of microorganisms: Tracking the spread of difficult-to-treat infections
2020-09-24 09:00 - 10:00 (America/New_York) | Webinar
AMR in the Light of COVID-19 – A Webinar Series
Each of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world.
About this Webinar:
Tracking the spread of COVID-19 has been critical to the global public health response. This information allows hospitals to prepare for surges, governments to deploy testing strategies, and citizens to modify their behavior appropriately. But while information about COVID-19 is readily and publicly available, the world still struggles to monitor and track the spread of drug resistant infections.How should global monitoring and data sharing evolve to combat antimicrobial resistance?
To learn more about the Antimicrobial Resistance Fighter Coalition, click here.
To learn more about this webinar series, click here.
To register for this webinar, click here.

Live Webinar: GARDP/REVIVE – Moving from preclinical to clinical-stage: Challenges and opportunities
2020-09-24 09:30 - 11:30 (America/New_York) | Webinar
Speakers:

Value of a pre-IND interaction with the US FDA during late lead optimization: Bugworks experience – Bala Subramanian, Bugworks Research Inc.
Amicidins: Building clinical and regulatory strategies for non-traditional products to prevent and treat life-threatening infections – Michael P. Bevilacqua, Amicrobe, Inc.
Discovery and development of microbiome therapeutics using reverse translation – Matthew Henn & Chris Ford, Seres
Therapeutics Development of a multi-component toxoid vaccine for S. aureus – Regulatory challenges and opportunities – M. Javad Aman & Catherine Bernard, Integrated BioTherapeutics
Regulatory challenges for RaPID/BSI – culture-free identification and characterization of bloodstream infections – David Steinmiller, HelixBind Inc.

Moderator: Erin Duffy, CARB-X
The presentation will be followed by a Q&A session.
Register now for this live webinar.

World Vaccine Congress
2020-09-28 - 2020-10-01 | Webinar
CARB-X speakers include Nadia Cohen, Alliance Manager.
The World Vaccine Congress is an award-winning series of conferences and an exhibition that has grown to become the largest and most established vaccine meeting of its kind across the globe. Due to the global pandemic, we have made a decision to run the 2020 congress VIRTUALLY. To mobilize, coordinate and align funding to enable the research needed to tackle this crisis and stop the outbreak, and commit with our experts how you can learn mechanisms for continuing scientific interactions and collaborations, now and beyond the congress.

Click here to view the agenda.
Click here to learn more.
Click here to register.
Nadia Cohen will be participating in the panel, World Vaccine Congress: Success case study 2 – Partnering with a non-profit for the first toxoid based multivalent vaccine for MRSA, on September 29 at 2:40 pm – 3:10 pm ET.

Longitude Prize Sprint Workshop: How to Attract Investment
2020-09-30 09:00 - 12:15 (America/New_York) | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Recent CARB-X graduate, Specific Diagnostics, will be participating in this workshop.
This workshop will be a forum for start-up and SMEs developing diagnostic tests to:

Hear from successful entrepreneurs who have built diagnostic companies, what do they think were their key factors for success?
Hear from venture capital investors about what they expect and need before making investments.
Meet in small break-out sessions in which you will interact directly with other medtech startups who have built or are in midst of building their enterprises and share insights.
Participate in panel discussion where you can ask both medtech leaders and venture capital fund managers about the intricacies and nuances of dilutive fund raise.

Note: this webinar is the second in the Longitude Prize Sprint series.
More details can be found on the Longitude Prize website here. Registration is limited, if you have trouble registering please send an email to longitude.prize@nesta.org.uk
To view the agenda, click here.
To register, click here.

Boston Area Antimicrobial Resistance Network (BAARN) Meeting
2020-10-02 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
CARB-X speakers include Su Chiang, Alliance Manager.
The 7th BAARN meeting will bring together the leading voices in academia and industry to addresss a defining global health crisis of our age: antibiotic resistant infection.
This year will be BAARN’s inaugural virtual meeting. We are using online platforms to present an amazing lineup of researchers and innovators, accessible to anyone with an internet connection. The event will stream on YOUTUBE LIVE. Zoom and YouTube Live links will be sent upon registration.
This event is co-coordinated by the Harvard Microbial Sciences Initiative and the Harvard Infectious Disease Institute.
To learn more, click here.
To register, click here.

World Antimicrobial Resistance Congress 2020
2020-10-08 - 2020-10-09
Erin Duffy, CARB-X Chief of R&D, is the chairperson of the event as well as a participant in a number of panels. Other participants from CARB-X include Kevin Outterson (Executive Director), Richard Alm (Therapeutic R&D Alliance Director), Ed Buurman (Prevention R&D Alliance Director) and Betsy Wonderly Trainor (Diagnostic R&D Alliance Director).

The 6th annual World Antimicrobial Resistance Congress will be held virtually October 8-9, 2020. It will showcase more than 250 presentations, including speakers from CARB-X funded companies, Forge and Entasis.
Anti-microbial resistance continues to grow as a critical healthcare crisis globally. The number of deaths attributed to this epidemic is exponentially increasing, and most measures and policies to combat AMR are deemed insufficient.Since 2015, the World Anti-Microbial Resistance Congress has been the go-to conference globally for all stakeholders in the AMR space to meet, brainstorm ideas and formulate initiatives that can effectively tackle this pressing issue.
Industry leaders, innovative technology and solution providers, public authorities, international organizations, infectious disease clinicians, pharmacists and microbiologists are some of the 1,000+ attendees from over 50 countries who will gather virtually this October 2020 at the World Anti-Microbial Resistance Congress.
If you work in these key areas of AMR, then you must attend the World Anti-Microbial Resistance Congress 2020!

Click here for more information.
Click here to register.

Antimicrobial Resistance Fighter Coalition Webinar: Prevention is stronger than a cure
2020-10-15 09:00 - 10:00 (America/New_York) | Webinar
AMR in the Light of COVID-19 – A Webinar Series
Each of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world.
About this Webinar:
Preventing drug resistant infections reduces the use of antibiotics and improves patient outcomes. Infection control practices, from simple hand-washing to global vaccination, and the use of effective infection prevention measures are key tools to combat COVID-19 and AMR. How has the COVID-19 pandemic informed our infection prevention efforts for healthcare systems and individuals around the world?
To learn more about the Antimicrobial Resistance Fighter Coalition, click here.
To learn more about this webinar series, click here.
To register for this webinar, click here.

5th Microbiome Movement - Drug Development Summit 2020
2020-10-19 - 2020-10-21 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
The study of the human microbiome remains one of the most exciting frontiers in modern medicine that if targeted correctly, has the potential to benefit millions of patients suffering from numerous diseases. However, the potential for effective medicines powered by the microbiome is matched by the unique challenges in developing them.
The Microbiome Movement – Drug Development Summit returns as the “must attend meeting for the translational microbiome community” to help cutting-edge pharmaceutical and academic researchers pursue the causal role of the human microbiome in disease to help deliver a new generation of targeted therapeutics, biomarker and diagnostics that demonstrate consistent clinical outcomes and predictabe MoAs.
So whether you’re part of a microbiome-focused biotech, a pharmaceutical organization assessing this exciting field, or an academic researcher with breakthrough findings, join the Microbiome Movement as we explore the global advances in translational microbiome research, and meet like-minded peers who are continuing to understand the causal and therapeutic potential of the ‘second genome’.
Click here to learn more.
Click here to view the agenda.
Click here to register.

World Vaccine Congress Europe: Changing the paradigm and finding a sustainable way to tackle AMR - The need for alternatives to antibiotics
2020-10-19 04:05 (America/New_York) | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
CARB-X speakers include Ed Buurman, Alliance Director.
Topics covered include:

How big is the problem economically speaking?
Should we phase out broad-spectrum antibiotics?
Programmatic & technical challenges
What can vaccines bring?

Click here to view the agenda.
Click here to learn more.
Click here to register.

IDWeek 2020
2020-10-21 - 2020-10-25 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
To learn more, click here.
To view the program, click here.
To register, click here.

38th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2020)
2020-10-26 - 2020-10-29 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
The 38th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2020) will be held on 26-29 October 2020 as a fully virtual meeting.
The organization of the meeting is a joint effort of ESPID members from the Netherlands. The ESPID forms the basis for investigators interested in infectious diseases in children and infection prevention in childhood. The main intent of the meeting is to bring together the most prominent researchers in and relevant to the field of paediatric infectious diseases and immunology. The meeting will provide an opportunity to exchange knowledge and generate new ideas in a relaxed, smart albeit casual atmosphere.
To learn more, click here.
To view the program, click here.
To register, click here.

BARDA Industry Day
2020-10-27 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
BARDA Industry Day is the annual meeting held to increase potential partner’s awareness of U.S. Government medical countermeasure priorities, interact with BARDA and ASPR staff, and network with public and private sector colleagues working in the Health Security space. This year, BARDA Industry Day 2020 will be virtual and will feature one day of exciting speakers, breakout sessions, and valuable networking opportunities! The primary mission of BARDA’s industry day is to advance innovation and development of medical countermeasures, bring together potential collaborators from across organizations, share our accomplishments among our stakeholders, and provide BARDA’s vision for the upcoming year’s priorities.
BARDA, through the CARB-X and Drive programs, is supporting a networks of wrap-around-service-oriented accelerators that can be leveraged to prepare partners for donor funding. The hope is to fill and maintain a pipeline of partners ready and able to apply for advanced research support while bolstering the market of life-saving countermeasures. DRIVE and CARB-X will organize a panel of BARDA supported accelerators who will describe how “wrap-around services” have actually lead to better products (fitting the BID theme of ‘responding together’. At the end of the panel, we will moderate a Q&A with audience members. Promotional material from other accelerators will be made available digitally for audience members.
To learn more, click here.

Live Webinar: GARDP/REVIVE – Developing antibiotics for children – medical need and regulatory challenges
2020-10-28 04:00 - 05:30 (America/New_York)
Speakers:
Phoebe Williams, Sydney Children’s Hospital and University of Sydney (Australia), will discuss:

Status quo – what antibiotics do we have (left) for children and babies
Where is the biggest medical need?
Challenges of clinical trials in children – the clinicians perspective
What impact will new drugs have in day-to-day practice and how does this depend on the setting (e.g. LMICs vs. high-income; community vs. hospital)?

Irja Lutsar, University of Tartu (Estonia), will discuss:

Clinical development of antibiotics for children; incl. new formulations of existing antibiotics including general regulatory requirements
Brief overview of the type of data required for a new antibiotic for paediatric use; i.e. PK and other data
Challenges of clinical trials in children and babies – the drug developers/regulatory perspective

Moderator: Sally Ellis (GARDP)
The presentations will be followed by a Q&A session.
To learn more, click here.

Interdisciplinary Course on Antibiotics and Resistance (ICARe) Webinar:
2020-10-29 16:00 - 18:00 (Europe/Paris) | Webinar
Panelists include Erin Duffy, CARB-X Chief of R&D
Please join us for a special ICARe webinar in light of the course’s 5th anniversary. This two-hour event, hosted by ICARe director Patrice Courvalin (Institut Pasteur, France), will feature four 20-minute presentations from leading experts in antimicrobial resistance and antibiotic discovery research. Presentations will follow with a 30-minute panel discussion.
The webinar schedule is as follows:

4:00: Patrice Courvalin (Institut Pasteur, France) – Introduction
4:05: Helen Boucher (Tufts Medical Center, USA) – “Syndemics of AMR and COVID”
4:25: Gerry Wright (McMaster University, Canada) – “What’s new in antibiotic resistance?”
4:45: Erin Duffy (CARB-X, USA) – “Innovation in antibiotic discovery”
5:05: John Rex (F2G, UK)- “Prospects and remaining challenges in antibiotic development”
5:25: Panel Discussion
5:55: Patrice Courvalin (Institut Pasteur, France) – Closing Remarks

To learn more, click here.
To register, click here.
After registering, you will receive a confirmation email containing information about joining the webinar. Please note that the webinar start time is in Paris Time.​

Antimicrobial Resistance Fighter Coalition Webinar: Aiming in the dark: what happens when disease spreads without diagnosis
2020-11-05 09:00 - 10:00 (America/New_York) | Webinar
Panelists include Erin Duffy, CARB-X Chief of R&D
AMR in the Light of COVID-19 – A Webinar Series
Each of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world.
About this Webinar:
The pandemic has demonstrated the critical role of diagnostic testing to steer our public health response. It has been shown that diagnostic testing for bacterial and fungal infections results in improved use of antibiotics and antibiotic stewardship. But whereas testing for COVID-19 has benefited from innovation and rapid uptake, testing for drug resistant infections remains underutilized. How can we improve the effective use of diagnostics, globally, for the diagnosis of bacterial and viral infections?
To learn more about the Antimicrobial Resistance Fighter Coalition, click here.
To learn more about this webinar series, click here.
To register for this webinar, click here.

FDA Public Workshop: Potential Approach for Ranking of Antimicrobial Drugs According to Their Importance in Human Medicine: A Risk Management Tool for Antimicrobial New Animal Drugs
2020-11-16 | Webinar
The Food and Drug Administration (FDA, the Agency, or we) is hosting a virtual public meeting entitled “Potential Approach for Ranking of Antimicrobial Drugs According to Their Importance in Human Medicine: A Risk Management Tool for Antimicrobial New Animal Drugs.” The purpose of the meeting is to obtain early input from the public on a potential revised approach for considering the human medical importance of antimicrobial new animal drugs when assessing and managing the antimicrobial resistance risks associated with the use of antimicrobial drugs in animals. The Agency is seeking public input on a potential revised process for ranking antimicrobials according to their relative importance in human medicine, on the potential criteria for their ranking, and on the resulting ranked list of antimicrobial drugs. A concept paper describing this potential revised process will be made available for discussion at the public meeting.
Click here to learn more.
Click here for the concept paper posted in advance of the meeting.
